Quintet Private Bank Europe S.A. Acquires 56,052 Shares of Merck & Co., Inc. $MRK

Quintet Private Bank Europe S.A. lifted its holdings in Merck & Co., Inc. (NYSE:MRK) by 19.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 337,040 shares of the company’s stock after purchasing an additional 56,052 shares during the quarter. Merck & Co., Inc. comprises 2.3% of Quintet Private Bank Europe S.A.’s holdings, making the stock its 12th biggest position. Quintet Private Bank Europe S.A.’s holdings in Merck & Co., Inc. were worth $48,975,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of MRK. Cardano Risk Management B.V. bought a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $1,012,530,000. Dimensional Fund Advisors LP raised its holdings in shares of Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after acquiring an additional 2,969,856 shares during the period. Bank of America Corp DE lifted its position in Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after acquiring an additional 2,919,780 shares in the last quarter. Corient Private Wealth LLC boosted its stake in Merck & Co., Inc. by 114.7% in the 4th quarter. Corient Private Wealth LLC now owns 5,210,548 shares of the company’s stock worth $548,462,000 after purchasing an additional 2,783,482 shares during the period. Finally, Employees Provident Fund Board bought a new position in Merck & Co., Inc. during the 4th quarter worth about $254,206,000. 76.07% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Cantor Fitzgerald upped their price objective on Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a research report on Thursday. Rothschild & Co Redburn lifted their target price on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, July 6th. CICC Research started coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target for the company. Guggenheim raised their price target on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Monday. Seventeen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus price target of $151.32.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst targets remain above the stock price. Cantor Fitzgerald raised its price target from $120 to $145 while maintaining a neutral rating. Morgan Stanley trimmed its target from $179 to $177 but retained an overweight rating, implying substantial potential upside. Cantor Fitzgerald raises pharma price targets
• Positive Sentiment: Longer-term growth arguments remain intact. Recent analysis points to continued Keytruda demand, newer products and pipeline assets as potential support for Merck’s outlook after 2028, helping offset concerns about upcoming patent expirations. Merck stock dip and buying opportunity analysis
• Neutral Sentiment: Merck paid its shareholder distribution. The dividend reinforces Merck’s income appeal, although the payment itself is unlikely to materially change the company’s near-term earnings outlook. Merck shareholder payment
• Negative Sentiment: A Dutch court sided with Halozyme Therapeutics in a patent dispute, barring Merck from selling subcutaneous Keytruda in eight European markets. The ruling threatens the rollout of a more convenient formulation of Merck’s key cancer drug and could increase investor concern about competitive and patent-related risks. Merck may appeal. Merck Keytruda European legal setback
• Negative Sentiment: Merck is viewed as the pharmaceutical company most exposed to near-term generic competition. Analysts expect industrywide patent losses to arrive in waves, raising concerns about revenue durability and the need for successful replacement products. Pharmaceutical patent losses and Merck exposure

Merck & Co., Inc. Stock Down 1.2%

MRK traded down $1.68 on Thursday, hitting $141.11. 2,345,448 shares of the company were exchanged, compared to its average volume of 10,629,651. The stock’s fifty day moving average is $143.34 and its 200-day moving average is $127.96. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company has a market cap of $348.15 billion, a PE ratio of 112.71, a PEG ratio of 6.18 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the previous year, the firm earned $2.13 EPS. The business’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.